Skip to main content

Table 1 Safety and efficacy of combination treatment in patients with advanced HCC

From: Emerging agents and regimens for hepatocellular carcinoma

Combinations Number of patients ORR (RECIST v1.1) Median PFS (months) Grade 3/4 AE Reference
Apatinib + camrelizumab 16 (second line) 50% 5.8 NA Xu et al. [54]
Lenvatinib + pembrolizumab 30 (26/30 as first line) 53.3% 9.7 NA Kudo [81]
Bevacizumab + atezolizumab 68 (first line) 34% 14.9 25% Pishvaian et al. [82]
Durvalumab + tremelimumab 40 (first and second line) 25% NA 25% Kelley et al. [83]
Ipilimumab + nivolumab 148 (second line) 31% NA 37% Yau et al. [65]
Axitinib + avelumab 22 (first line) 13.6% 5.5 72.7% Kudo et al. [84]
FOLFOX4 + camrelizumab 34 (first line) 26.5% 5.5 5.9% Qin et al. [85]
  1. ORR objective response rate, PFS progression-free survival, AE adverse events, NA not available